Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04115254 · ClinicalTrials.gov registry record · NA

Stereotactic Magnetic Resonance Guided Radiation Therapy

A NA study of Prostate Cancer and Lung Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
397
Enrollment target
2
Study locations

NCT04115254 is a NA study of Prostate Cancer and Lung Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 397 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04115254, a NA study of Prostate Cancer and Lung Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
397 participants
Enrollment target
2
Study locations

Study Summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Interventions

  • RADIATION MR-guided Linac

Study Locations (2)

Massachusetts

  • Brigham & Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 397 participants
Start Date 2019-10-22
Est. Completion 2028-06
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04115254

The ClinicalTrials.gov registry entry for NCT04115254 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MR-guided Linac is the first listed.

NCT04115254 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04115254 about?

NCT04115254 is a clinical study titled "Stereotactic Magnetic Resonance Guided Radiation Therapy". This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph...

What is the current status of trial NCT04115254?

This trial is currently recruiting. It is a NA study. The enrollment target is 397 participants. The study started on 2019-10-22. Estimated completion is 2028-06.

What conditions does trial NCT04115254 study?

This clinical trial studies the following conditions: Prostate Cancer, Lung Cancer, Pancreas Cancer, Mesothelioma, Renal Cancer.

What interventions are being tested in trial NCT04115254?

The interventions under investigation include: MR-guided Linac (RADIATION).

Who is sponsoring clinical trial NCT04115254?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04115254 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.